Hui Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hui Jiang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Nelson Ong'Ondo Gekara
Institute of Medical Microbiology and Hygiene, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany
5 shared publications - Jianghuai Liu
State Key Laboratory of Pharmaceutical Biotechnology, Model Animal Research Center at Medical School of Nanjing University, Nanjing, 210061, China.
3 shared publications Man Sun
State Key Laboratory of Pharmaceutical Biotechnology and Ministry of Education Key Laboratory of Model Animals for Disease Study, Model Animal Research Center of Nanjing University, Nanjing 210061, China; and
2 shared publicationsQingzhou Meng
State Key Laboratory of Pharmaceutical Biotechnology and Ministry of Education Key Laboratory of Model Animals for Disease Study, Model Animal Research Center of Nanjing University, Nanjing 210061, China; and
2 shared publicationsSwarupa Panda
The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå, Sweden
2 shared publications- Ajinkya S. Kawale
Department of Pharmacology and Toxicology and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
1 shared publication
Latest Publications
- Open Access
- 14 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (33)
Inflammatory kinase TBK1 suppresses homologous recombination DNA repair to sensitize tumors to chemotherapy
Inflammation exerts context-dependent influences on tumor progression and therapeutic response. Although chemotherapy remains a cornerstone of cancer treatment, its functional interplay with inflammatory signaling is still incompletely understood. Here, we identify TANK-binding kinase 1 (TBK1) as a critical modulator of chemotherapeutic efficacy through its impact on DNA damage repair. TBK1 activation potentiates cancer-cell death induced by chemotherapeutic agents by promoting DNA damage and impairing homologous recombination (HR) repair. This effect occurs independently of canonical inflammatory cytokines, as demonstrated in IRF3- and p65- double deficient cells. Mechanistically, TBK1 suppresses recruitment of the key HR factor Meiotic Recombination 11 Homolog 1 (MRE11) to PARP1 at DNA-damage sites in a kinase-activity-dependent yet cytokine-independent manner. Furthermore, TBK1 activation correlates with enhanced p53 signaling and genomic instability, providing a molecular basis for its pro-death effects under chemotherapy. Collectively, these findings reveal a previously unrecognized function of TBK1 in modulating the DNA-damage response, linking inflammatory signaling to genome destabilization and identifying the TBK1–MRE11 axis as a potential target to enhance chemotherapeutic efficacy.
- 14 August 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (33)
Open AccessInflammatory kinase TBK1 suppresses homologous recombination DNA repair to sensitize tumors to chemotherapy
Inflammation exerts context-dependent influences on tumor progression and therapeutic response. Although chemotherapy remains a cornerstone of cancer treatment, its functional interplay with inflammatory signaling is still incompletely understood. Here, we identify TANK-binding kinase 1 (TBK1) as a critical modulator of chemotherapeutic efficacy through its impact on DNA damage repair. TBK1 activation potentiates cancer-cell death induced by chemotherapeutic agents by promoting DNA damage and impairing homologous recombination (HR) repair. This effect occurs independently of canonical inflammatory cytokines, as demonstrated in IRF3- and p65- double deficient cells. Mechanistically, TBK1 suppresses recruitment of the key HR factor Meiotic Recombination 11 Homolog 1 (MRE11) to PARP1 at DNA-damage sites in a kinase-activity-dependent yet cytokine-independent manner. Furthermore, TBK1 activation correlates with enhanced p53 signaling and genomic instability, providing a molecular basis for its pro-death effects under chemotherapy. Collectively, these findings reveal a previously unrecognized function of TBK1 in modulating the DNA-damage response, linking inflammatory signaling to genome destabilization and identifying the TBK1–MRE11 axis as a potential target to enhance chemotherapeutic efficacy.
- Open Access
- 1 March 2023
- Published by Springer Nature in Cell Research
- Vol. 33 (4) , 325-327
Aspirin protects against genotoxicity by promoting genome repair
- 1 March 2023
- Published by Springer Nature in Cell Research
- Vol. 33 (4) , 325-327
Open AccessAspirin protects against genotoxicity by promoting genome repair
- Open Access
- 23 September 2019
- Published by Springer Nature in The EMBO Journal
- Vol. 38 (21) , e102718
Chromatin‐bound cGAS is an inhibitor of DNA repair and hence accelerates genome destabilization and cell death
DNA repair via homologous recombination (HR) is indispensable for genome integrity and cell survival but if unrestrained can result in undesired chromosomal rearrangements. The regulatory mechanisms of HR are not fully understood. Cyclic GMP‐AMP synthase (cGAS) is best known as a cytosolic innate immune sensor critical for the outcome of infections, inflammatory diseases, and cancer. Here, we report that cGAS is primarily a chromatin‐bound protein that inhibits DNA repair by HR, thereby accelerating genome destabilization, micronucleus generation, and cell death under conditions of genomic stress. This function is independent of the canonical STING‐dependent innate immune activation and is physiologically relevant for irradiation‐induced depletion of bone marrow cells in mice. Mechanistically, we demonstrate that inhibition of HR repair by cGAS is linked to its ability to self‐oligomerize, causing compaction of bound template dsDNA into a higher‐ordered state less amenable to strand invasion by RAD51‐coated ssDNA filaments. This previously unknown role of cGAS has implications for understanding its involvement in genome instability‐associated disorders including cancer.
- 23 September 2019
- Published by Springer Nature in The EMBO Journal
- Vol. 38 (21) , e102718
Open AccessChromatin‐bound cGAS is an inhibitor of DNA repair and hence accelerates genome destabilization and cell death
DNA repair via homologous recombination (HR) is indispensable for genome integrity and cell survival but if unrestrained can result in undesired chromosomal rearrangements. The regulatory mechanisms of HR are not fully understood. Cyclic GMP‐AMP synthase (cGAS) is best known as a cytosolic innate immune sensor critical for the outcome of infections, inflammatory diseases, and cancer. Here, we report that cGAS is primarily a chromatin‐bound protein that inhibits DNA repair by HR, thereby accelerating genome destabilization, micronucleus generation, and cell death under conditions of genomic stress. This function is independent of the canonical STING‐dependent innate immune activation and is physiologically relevant for irradiation‐induced depletion of bone marrow cells in mice. Mechanistically, we demonstrate that inhibition of HR repair by cGAS is linked to its ability to self‐oligomerize, causing compaction of bound template dsDNA into a higher‐ordered state less amenable to strand invasion by RAD51‐coated ssDNA filaments. This previously unknown role of cGAS has implications for understanding its involvement in genome instability‐associated disorders including cancer.
- 11 June 2019
- Published by Elsevier
- Vol. 625, 339-350
TUBE and UbiCRest assays for elucidating polyubiquitin modifications in protein complexes
- 11 June 2019
- Published by Elsevier
- Vol. 625, 339-350
TUBE and UbiCRest assays for elucidating polyubiquitin modifications in protein complexes
- 14 May 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 12 (581) , eaax3521
The innate immune DNA sensor cGAS: A membrane, cytosolic, or nuclear protein?
Interaction with membrane phospholipids restricts the localization of the DNA sensor cGAS and limits its activity.
- 14 May 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 12 (581) , eaax3521
The innate immune DNA sensor cGAS: A membrane, cytosolic, or nuclear protein?
Interaction with membrane phospholipids restricts the localization of the DNA sensor cGAS and limits its activity.
- 1 January 2019
- Published by Elsevier
- Vol. 625, 299-307
Comet and micronucleus assays for analyzing DNA damage and genome integrity
- 1 January 2019
- Published by Elsevier
- Vol. 625, 299-307
Comet and micronucleus assays for analyzing DNA damage and genome integrity
- 1 October 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (7) , 2880-2890
PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense
Signaling by viral nucleic acids and subsequently by type I IFN is central to antiviral innate immunity. These signaling events are also likely to engage metabolic changes in immune and nonimmune cells to support antiviral defense. In this study, we show that cytosolic viral recognition, by way of secondary IFN signaling, leads to upregulation of glycolysis preferentially in macrophages. This metabolic switch involves induction of glycolytic activator 6-phosphofructose-2-kinase and fructose-2,6-bisphosphatase (PFKFB3). Using a genetic inactivation approach together with pharmacological perturbations in mouse cells, we show that PFKFB3-driven glycolysis selectively promotes the extrinsic antiviral capacity of macrophages, via metabolically supporting the engulfment and removal of virus-infected cells. Furthermore, the antiviral function of PFKFB3, as well as some contribution of its action from the hematopoietic compartment, was confirmed in a mouse model of respiratory syncytial virus infection. Therefore, different from the long-standing perception of glycolysis as a proviral pathway, our findings establish an antiviral, immunometabolic aspect of glycolysis that may have therapeutic implications.
- 1 October 2016
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 197 (7) , 2880-2890
PFKFB3-Driven Macrophage Glycolytic Metabolism Is a Crucial Component of Innate Antiviral Defense
Signaling by viral nucleic acids and subsequently by type I IFN is central to antiviral innate immunity. These signaling events are also likely to engage metabolic changes in immune and nonimmune cells to support antiviral defense. In this study, we show that cytosolic viral recognition, by way of secondary IFN signaling, leads to upregulation of glycolysis preferentially in macrophages. This metabolic switch involves induction of glycolytic activator 6-phosphofructose-2-kinase and fructose-2,6-bisphosphatase (PFKFB3). Using a genetic inactivation approach together with pharmacological perturbations in mouse cells, we show that PFKFB3-driven glycolysis selectively promotes the extrinsic antiviral capacity of macrophages, via metabolically supporting the engulfment and removal of virus-infected cells. Furthermore, the antiviral function of PFKFB3, as well as some contribution of its action from the hematopoietic compartment, was confirmed in a mouse model of respiratory syncytial virus infection. Therefore, different from the long-standing perception of glycolysis as a proviral pathway, our findings establish an antiviral, immunometabolic aspect of glycolysis that may have therapeutic implications.
- Open Access
- 5 June 2015
- Published by Springer Nature in Cell Research
- Vol. 25 (7) , 877-880
Functional annotation of cis-regulatory elements in human cells by dCas9/sgRNA
- 5 June 2015
- Published by Springer Nature in Cell Research
- Vol. 25 (7) , 877-880
Open AccessFunctional annotation of cis-regulatory elements in human cells by dCas9/sgRNA
- Open Access
- 8 November 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11) , e27464
Regulation of Interleukin-10 Receptor Ubiquitination and Stability by Beta-TrCP-Containing Ubiquitin E3 Ligase
Interleukin-10 (IL-10) initiates potent anti-inflammatory effects via activating its cell surface receptor, composed of IL-10R1 and IL-10R2 subunits. The level of IL-10R1 is a major determinant of the cells' responsiveness to IL-10. Here, via a series of biochemical analyses using 293T cells reconstituted with IL-10R1, we identify the latter as a novel substrate of βTrCP-containing ubiquitin E3 ligase. Within the intracellular tail of IL-10R1, a canonical (318DpSGFGpS) and a slightly deviated (369DpSGICLQEP) βTrCP recognition motif can additively recruit βTrCP in a phosphorylation-dependent manner. βTrCP recruitment leads to ubiquitination, endocytosis and degradation of IL-10R1, subsequently reducing the cellular responsiveness to IL-10. Our study uncovers a novel negative regulatory mechanism that may potentially affect IL-10 function in target cells under physiological or pathological conditions.
- 8 November 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (11) , e27464
Open AccessRegulation of Interleukin-10 Receptor Ubiquitination and Stability by Beta-TrCP-Containing Ubiquitin E3 Ligase
Interleukin-10 (IL-10) initiates potent anti-inflammatory effects via activating its cell surface receptor, composed of IL-10R1 and IL-10R2 subunits. The level of IL-10R1 is a major determinant of the cells' responsiveness to IL-10. Here, via a series of biochemical analyses using 293T cells reconstituted with IL-10R1, we identify the latter as a novel substrate of βTrCP-containing ubiquitin E3 ligase. Within the intracellular tail of IL-10R1, a canonical (318DpSGFGpS) and a slightly deviated (369DpSGICLQEP) βTrCP recognition motif can additively recruit βTrCP in a phosphorylation-dependent manner. βTrCP recruitment leads to ubiquitination, endocytosis and degradation of IL-10R1, subsequently reducing the cellular responsiveness to IL-10. Our study uncovers a novel negative regulatory mechanism that may potentially affect IL-10 function in target cells under physiological or pathological conditions.